Tumor-specific cell surface proteins are attractive targets for diverse therapeutic strategies, including radiation-based and immunotherapy approaches. However, significant inter- and intra-tumoral heterogeneity in their surface levels poses a major challenge to clinical efficacy and can contribute to therapy resistance. Our lab seeks to understand the regulatory networks that control the expression and dynamics of tumor-associated surface proteins. By defining these mechanisms, we aim to develop rational combinatorial strategies to enhance the precision and effectiveness of targeted cancer therapies.